Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDECT 2: 124I-Girentuximab PET/CT for Renal Masses
NCT01762592Phase 3Withdrawn
- Sponsor
- Heidelberg Pharma AG
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of girentuximab in clear cell renal cell carcinoma (ccRCC), sponsored by Heidelberg Pharma AG. Planned start Dec 2017; status: withdrawn.
02
Drugs
girentuximab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01762592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01762592.